SCHEMBL23923776

SCHEMBL23923776

COC(=O)c1[nH]c(C)cc1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 5/20 0.42
HPGD P15428 3/20 0.42
HSD17B10 Q99714 2/20 0.42
MAPT P10636 3/20 0.42
CYP3A4 P08684 2/20 0.40
ACHE P22303 1/20 0.40
CYP1A2 P05177 1/20 0.40
MAPK14 Q16539 2/20 0.39
RAF1 P04049 1/20 0.39
NPSR1 Q6W5P4 3/20 0.39
GAA P10253 3/20 0.39
HTT P42858 1/20 0.39
PADI4 Q9UM07 1/20 0.39
XDH P47989 3/20 0.38
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA7 P43166 2/20 0.38
CA9 Q16790 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28618724 0.82 CYP1A2 (0.52) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL257250 0.80 ALDH1A1 (0.62) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL16240346 0.79 LMNA (0.42) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL23758516 0.78 ALDH1A1 (0.40) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL23923476 0.77 MAPT (0.38) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL3281275 0.76 GAA (0.44) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL22302580 0.76 ALDH1A1 (0.44) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL3728873 0.76 CYP1A2 (0.40) ALDH1A1MAPTCYP3A4CYP1A2NPSR1
SCHEMBL1044787 0.76 NOTUM (0.41) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL18845424 0.74 TSHR (0.43) ALDH1A1KDM4EHPGDHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122010912-A Antiviral 1, 3-dioxoindene compounds 诺华股份有限公司 2026-05-12 CN disclosed
US-20250188066-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-06-12 US disclosed
US-12286423-B2 Antiviral 1,3-di-oxo-indene compounds NOVARTIS AG (CH) 2025-04-29 US disclosed
CN-115867545-A Antiviral 1,3 dioxoindene compounds 诺华股份有限公司 2023-03-28 CN disclosed
EP-4139301-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS Novartis AG (CH) 2023-03-01 EP disclosed
CN-112552901-B Ratio type zinc ion fluorescent probe and preparation and application thereof 浙江大学城市学院 2022-06-21 CN disclosed
WO-2021214080-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS NOVARTIS AG (CH) 2021-10-28 WO disclosed
WO-2021214080-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS NOVARTIS AG (CH) 2021-10-28 WO disclosed
US-20210323947-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS NOVARTIS AG (CH) 2021-10-21 US disclosed
US-20210323947-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS NOVARTIS AG (CH) 2021-10-21 US disclosed
CN-112552901-A Ratio type zinc ion fluorescent probe and preparation and application thereof 浙江大学城市学院 2021-03-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188066-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS IRF3, EIF2AK2, ZC3HAV1 ALDH1A1 1239/4885KDM4E 3114/4885HPGD 2579/4885
US-20210323947-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS IRF3, EIF2AK2, ZC3HAV1 ALDH1A1 1239/4885KDM4E 3114/4885HPGD 2579/4885
US-12286423-B2 Antiviral 1,3-di-oxo-indene compounds IRF3, EIF2AK2, ZC3HAV1 ALDH1A1 1239/4885KDM4E 3114/4885HPGD 2579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.